BiotechTube
Genosco

Genosco

Cambridge, United States· Est.
genosco.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Genosco is a U.S.-based, clinical-stage biotech founded in 2018 with a core focus on kinase-targeted therapies. The company's differentiation lies in its proprietary discovery platform, GENO-K™/GENO-D™, designed to identify rare kinase sequences and develop selective inhibitors and protein degraders. Its pipeline includes both internally discovered assets and partnered programs, with lead candidates like a ROCK2 inhibitor entering Phase 1 and a legacy asset, lazertinib, already approved in combination therapies. The company appears to be a subsidiary of Oscotec Inc. and operates with a mix of independent R&D and strategic partnerships.

OncologyFibrotic DiseasesHematology

Technology Platform

Proprietary GENO-K™/GENO-D™ integrated platform. GENO-K™ is a kinase-focused protein database and ligand library for identifying rare sequences to develop selective inhibitors. GENO-D™ is a targeted protein degrader (TPD) platform with a degrader library and design technology for developing kinase degraders.

Opportunities

The recent FDA IND clearance for its lead internal ROCK2 inhibitor (GNS-3545) provides a near-term catalyst for clinical validation.
The company's targeted protein degradation (TPD) program represents a long-term opportunity to tackle historically 'undruggable' oncology targets like MYC, positioning it at the forefront of a next-generation therapeutic modality.

Risk Factors

Genosco faces high clinical development risk as its lead proprietary assets are in early stages.
The company operates in the intensely competitive kinase inhibitor space and must demonstrate clear differentiation for its candidates.
Its financial and strategic dependence on its parent company, Oscotec, introduces an element of external control.

Competitive Landscape

Genosco competes in the crowded kinase inhibitor market against large pharma and numerous biotechs. Its differentiation strategy relies on its platform's ability to generate highly selective compounds for rare kinase sequences and its foray into kinase-targeted protein degradation, a newer and less saturated field where it faces competition from dedicated TPD companies.

More companies in United States →